Docrates Oy
- Address
- Saukonpaadenranta 2, 00180 Helsinki, Finland
Docrates Oy - Advanced Oncology Research Center
Docrates Oy is a specialized oncology research center with extensive expertise in Phase I-III clinical trials for advanced solid tumors. The center demonstrates particular strength in investigating novel targeted therapies and immunotherapies across multiple cancer types, with a focus on precision medicine approaches for treatment-resistant malignancies.
- Advanced prostate cancer therapeutics, including metastatic castration-resistant prostate cancer (mCRPC) with combination PARP inhibitor and hormonal therapy strategies
- Non-small cell lung cancer (NSCLC) research, featuring HER2-mutated and PD-L1 high tumor investigations with next-generation immunotherapy combinations
- Innovative oncolytic virus therapies, including TNF-alpha and IL-2 coding adenovirus platforms combined with checkpoint inhibitors
- HER2-positive gastrointestinal malignancies, including biliary tract cancer and colorectal cancer with targeted bispecific antibody approaches
The center's portfolio reflects a commitment to precision oncology and biomarker-driven clinical development, with particular emphasis on combining novel agents with established therapies. Their work encompasses advanced ovarian neoplasms, melanoma, and squamous cell carcinoma of the head and neck (SCCHN), demonstrating capabilities in managing patients with resistant disease and evaluating cutting-edge therapeutic modalities including antibody-drug conjugates and oncolytic immunotherapy platforms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Docrates Oy
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3) | Pfizer Inc. | Phase III | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2021-03-17 | 2024-10-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.